mental health issue
Mental health clinical trials span depression, anxiety, bipolar disorder, schizophrenia, eating disorders, ADHD, sleep disorders, and substance use disorders — representing the most prevalent category of disability-causing conditions globally. Mental health research is undergoing a paradigm shift as biological understanding deepens: from purely symptom-based diagnosis to biomarker-informed phenotyping, and from first-generation neurotransmitter-targeting drugs to precision approaches based on neurocircuit function, genetics, and inflammatory markers.
Active trial areas include psychedelic-assisted psychotherapy (psilocybin, MDMA, ketamine), digital therapeutics validated as prescription medical devices, transcranial magnetic stimulation with personalized targeting using fMRI biomarkers, inflammatory markers (CRP, IL-6) as predictors of antidepressant response, and integrated care models combining pharmacotherapy with technology-delivered psychosocial support. ADHD trials increasingly focus on non-stimulant agents to address cardiovascular safety concerns in adults.
Most mental health trials require a structured diagnostic interview (SCID or MINI) to confirm diagnosis; severity scales (PHQ-9, GAD-7, PANSS) determine eligibility and serve as primary endpoints.